Steven W Andrews
Overview
Explore the profile of Steven W Andrews including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ashraf S, Bouhana K, Pheneger J, Andrews S, Walsh D
Arthritis Res Ther
. 2016 May;
18(1):97.
PMID: 27145816
Background: Inflammation is an essential component of arthritis pain. Nerve growth factor (NGF) plays a key role in acute and chronic pain states especially those associated with inflammation. NGF acts...
2.
Jiang Y, Andrews S, Condroski K, Buckman B, Serebryany V, Wenglowsky S, et al.
J Med Chem
. 2013 May;
57(5):1753-69.
PMID: 23672640
HCV serine protease NS3 represents an attractive drug target because it is not only essential for viral replication but also implicated in the viral evasion of the host immune response...
3.
Shiozaki M, Maeda K, Miura T, Kotoku M, Yamasaki T, Matsuda I, et al.
J Med Chem
. 2011 Mar;
54(8):2839-63.
PMID: 21417219
Aggrecanases, particularly aggrecanase-1 (ADAMTS-4) and aggrecanase-2 (ADAMTS-5), are believed to be key enzymes involved in the articular cartilage breakdown that leads to osteoarthritis. Thus, aggrecanases are considered to be viable...
4.
Ghilardi J, Freeman K, Jimenez-Andrade J, Mantyh W, Bloom A, Bouhana K, et al.
Bone
. 2010 Sep;
48(2):389-98.
PMID: 20854944
Current therapies for treating skeletal pain have significant limitations as available drugs (non-steroidal anti-inflammatory drugs and opiates) have significant unwanted side effects. Targeting nerve growth factor (NGF) or its cognate...
5.
Shiozaki M, Imai H, Maeda K, Miura T, Yasue K, Suma A, et al.
Bioorg Med Chem Lett
. 2009 Sep;
19(21):6213-7.
PMID: 19767207
A series of 1-sulfonylaminocyclopropanecarboxylates was synthesized as ADAMTS-5 (Aggrecanase-2) inhibitors. After an intensive investigation of the central cyclopropane core including its absolute stereochemistry and substituents, we found compound 22 with...
6.
Shiozaki M, Maeda K, Miura T, Ogoshi Y, Haas J, Fryer A, et al.
Bioorg Med Chem Lett
. 2009 Feb;
19(6):1575-80.
PMID: 19243944
A series of N-substituted sulfonylamino-alkanecarboxylate ADAMTS-5 (Aggrecanase-2) inhibitors has been synthesized and the in vitro enzyme SAR is discussed. This report is the first example of carboxylate-based ADAMTS-5 inhibitors which...
7.
Rajagopalan R, Misialek S, Stevens S, Myszka D, Brandhuber B, Ballard J, et al.
Biochemistry
. 2009 Feb;
48(11):2559-68.
PMID: 19209850
The protease activity of hepatitis C virus nonstructural protein 3 (NS3) is essential for viral replication. ITMN-191, a macrocyclic inhibitor of the NS3 protease active site, promotes rapid, multilog viral...
8.
Seiwert S, Andrews S, Jiang Y, Serebryany V, Tan H, Kossen K, et al.
Antimicrob Agents Chemother
. 2008 Oct;
52(12):4432-41.
PMID: 18824605
Future treatments for chronic hepatitis C virus (HCV) infection are likely to include agents that target viral components directly. Here, the preclinical characteristics of ITMN-191, a peptidomimetic inhibitor of the...